Theriva Biologics, Inc. (TOVX)
0.253
0.00 (0.00%)
USD |
NYAM |
Sep 04, 16:00
0.2543
0.00 (0.00%)
After-Hours: 20:00
Theriva Biologics Research and Development Expense (Quarterly) : 1.268M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.268M |
| March 31, 2026 | 0.355M |
| December 31, 2025 | 1.132M |
| September 30, 2025 | 2.551M |
| June 30, 2025 | 1.953M |
| March 31, 2025 | 2.968M |
| December 31, 2024 | 2.886M |
| September 30, 2024 | 2.734M |
| June 30, 2024 | 2.953M |
| March 31, 2024 | 3.459M |
| December 31, 2023 | 4.196M |
| September 30, 2023 | 4.006M |
| June 30, 2023 | 3.133M |
| March 31, 2023 | 2.977M |
| December 31, 2022 | 3.071M |
| September 30, 2022 | 2.57M |
| June 30, 2022 | 3.485M |
| March 31, 2022 | 2.597M |
| December 31, 2021 | 2.779M |
| September 30, 2021 | 1.972M |
| June 30, 2021 | 1.932M |
| March 31, 2021 | 1.118M |
| December 31, 2020 | 0.979M |
| September 30, 2020 | 0.914M |
| June 30, 2020 | 1.603M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.635M |
| December 31, 2019 | 1.927M |
| September 30, 2019 | 4.144M |
| June 30, 2019 | 2.594M |
| March 31, 2019 | 2.418M |
| December 31, 2018 | 2.056M |
| September 30, 2018 | 2.846M |
| June 30, 2018 | 3.572M |
| March 31, 2018 | 3.37M |
| December 31, 2017 | 3.756M |
| September 30, 2017 | 4.137M |
| June 30, 2017 | 4.831M |
| March 31, 2017 | 6.059M |
| December 31, 2016 | 6.729M |
| September 30, 2016 | 7.061M |
| June 30, 2016 | 7.164M |
| March 31, 2016 | 8.155M |
| December 31, 2015 | 8.858M |
| September 30, 2015 | 10.05M |
| June 30, 2015 | 7.508M |
| March 31, 2015 | 6.494M |
| December 31, 2014 | 5.242M |
| September 30, 2014 | 3.693M |
| June 30, 2014 | 2.837M |
| March 31, 2014 | 2.717M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Yarrow Bioscience, Inc. | 0.788M |
| Nkarta, Inc. | 26.31M |
| Unicycive Therapeutics, Inc. | 2.788M |
| OnKure Therapeutics, Inc. | 12.51M |